Entry Detail

General Information

Database ID: LDA0003866
Species: Homo sapiens
Confidence Score: 0.985791
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Unknown

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:CDKN2B-AS1
Full Name:CDKN2B antisense RNA 1
Category:LncRNA
Species:Homo sapiens
Synonyms:ANRIL|CDKN2B-AS|CDKN2BAS|NCRNA00089|PCAT12|p15AS
Chromosome:9
Strand:+
Coordinate:
Start Site(bp):21994791End Site(bp):22121097
External Links:
Ensembl ID:ENSG00000240498
Ensembl Transcript ID:N/A
Entrez Gene:100048912.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:96   
More Information
Causal Disease Number:54
Network:
Top Causal Diseases:
Breast Neoplasms  (Score: 1)
Carcinoma, Hepatocellular  (Score: 1)
Carcinoma, Hepatocellular  (Score: 1)
Breast Neoplasms  (Score: 1)
Glioma  (Score: 0.999893)
Leukemia, Myeloid, Acute  (Score: 0.999893)
Ovarian Neoplasms  (Score: 0.999893)
Osteosarcoma  (Score: 0.999893)
Leukemia, Myeloid, Acute  (Score: 0.999893)
Glioma  (Score: 0.999893)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:D003928
Disease Name:Diabetic Nephropathies
Category:MeSH
Type:Urogenital Diseases
Define:KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
Alias:Diabetic Nephropathies//Nephropathies, Diabetic//Nephropathy, Diabetic//Diabetic Nephropathy//Diabetic Kidney Disease//Diabetic Kidney Diseases//Kidney Disease, Diabetic//Kidney Diseases, Diabetic//Diabetic Glomerulosclerosis//Glomerulosclerosis, Diabetic//Intracapillary Glomerulosclerosis//Nodular Glomerulosclerosis//Glomerulosclerosis, Nodular//Kimmelstiel-Wilson Syndrome//Kimmelstiel Wilson Syndrome//Syndrome, Kimmelstiel-Wilson//Kimmelstiel-Wilson Disease//Kimmelstiel Wilson Disease

 

Disease Association Statistics

Total Associated ncRNA Number:72   
More Information
Causal ncRNA Number:58
Network:
Top Causal ncRNAs:
MALAT1  (Score: 0.999998)
MALAT1  (Score: 0.999998)
MIAT  (Score: 0.985791)
MIAT  (Score: 0.985791)
CDKN2B-AS1  (Score: 0.985791)
circHIPK3  (Score: 0.985791)
circHIPK3  (Score: 0.985791)
CDKN2B-AS1  (Score: 0.985791)
CASC2  (Score: 0.731059)
CASC2  (Score: 0.731059)
More Information

 

Evidence Support

Strong Evidence:qRT-PCR//Transfection
Weak Evidence:

 

Reference

[1] PubMed ID:32726814
Disease Name:Diabetic Nephropathies
Sample:SV40-MES13 cells
Dysfunction Pattern:Regulation(Wnt/β-catenin and MEK/ERK pathways )
Validated Method:qRT-PCR//Transfection
Description:Lnc-ANRIL expression was significantly higher in HG-treated SV40-MES13 cells compared with normal glucose-treated SV40-MES13 cells and osmotic control-treated SV40-MES13 cells. Lnc-ANRIL knock-down suppressed cell proliferation and promoted cell apoptosis in HG-treated SV40-MES13 cells. As for fibrosis, lnc-ANRIL knock-down reduced fibronectin and collagen I expressions in HG-treated SV40-MES13 cells. Besides, the expressions of supernatant tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-1β, IL-6, IL-8 and IL-18 were reduced in Sh-ANRIL group compared with Sh-NC group. Furthermore, Wnt3, β-catenin, p-MEK1 and p-ERK1 expressions were suppressed in Sh-ANRIL group compared with Sh-NC group, which suggested that lnc-ANRIL knock-down inhibited Wnt/β-catenin and MEK/ERK pathways in HG-treated SV40-MES13 cells.
Causality:Yes
Causal Description:Lnc-ANRIL knock-down suppressed cell proliferation and promoted cell apoptosis in HG-treated SV40-MES13 cells. As for fibrosis, lnc-ANRIL knock-down reduced fibronectin and collagen I expressions in HG-treated SV40-MES13 cells. Besides, the expressions of supernatant tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-1β, IL-6, IL-8 and IL-18 were reduced in Sh-ANRIL group compared with Sh-NC group. Furthermore, Wnt3, β-catenin, p-MEK1 and p-ERK1 expressions were suppressed in Sh-ANRIL group compared with Sh-NC group, which suggested that lnc-ANRIL knock-down inhibited Wnt/β-catenin and MEK/ERK pathways in HG-treated SV40-MES13 cells.
Clinical-realted Application:

[2] PubMed ID:36129598
Disease Name:Diabetic Nephropathies
Sample:DKD patients
Dysfunction Pattern:Expression(highly expressed)
Validated Method:qRT-PCR
Description:The expression of ANRIL was significantly up-regulated in DKD patients (microalbuminuria, macroalbuminuria and renal dysfunction groups) than that in healthy control group. ANRIL was also over-expressed in macroalbuminuria and renal dysfunction groups in comparison with normalbuminuria group. ANRIL expression was positively correlated with Scr, BUN, CysC, urine β2-MG and urine α1-MG; while negatively correlated with eGFR in DKD patients. In addition, ANRIL was the risk factor for DKD with OR value of 1.681. The AUC of ANRIL in identifying DKD was 0.922, and the sensitivity and specificity of DKD diagnosis were 83.3% and 90.5%, respectively.
Causality:No
Causal Description:
Clinical-realted Application: